Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CATALYST BIOSCIENCES, INC. (CBIO)
|
Add to portfolio |
|
|
|
| Price: |
$5.00
| | Metrics |
| OS: |
38.0
|
M
| |
|
|
| Market cap: |
$190
|
M
| |
|
|
|
Net cash:
|
$6.92
|
M
| |
$0.18
|
per share
|
|
EV:
|
$183
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 7.3 | 20.9 | 0.0 | 0.0 | 1.0 | 0.4 | 1.8 | 1.8 |
| Revenue growth | -65.0% | | -100.0% | -99.4% | 155.1% | -77.2% | -3.5% | 246.7% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 7.3 | 20.9 | 0.0 | 0.0 | 1.0 | 0.4 | 1.8 | 1.8 |
| Gross margin | 100.0% | 100.0% | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | | | | | | | | |
| Research and development | 68.9 | 53.0 | 43.9 | 21.5 | 12.8 | 11.6 | 6.0 | 5.3 |
| General and administrative | 19.0 | 16.2 | 13.4 | 12.4 | 10.0 | 9.3 | 9.6 | 4.1 |
| EBIT | -87.9 | -57.4 | -57.3 | -33.8 | -21.8 | -20.4 | -13.8 | -7.5 |
| EBIT margin | -1197.8% | -273.9% | | -563700.0% | -2143.6% | -5117.3% | -788.7% | -414.2% |
| Pre-tax income | -87.9 | -56.2 | -55.2 | -30.1 | -21.6 | -16.9 | -14.8 | -6.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -87.9 | -56.2 | -55.2 | -30.1 | -25.5 | -16.9 | -14.8 | -6.6 |
| Net margin | -1197.9% | -268.5% | | -500916.7% | -2506.1% | -4246.9% | -843.5% | -364.8% |
| |
| Diluted EPS | ($2.87) | ($2.93) | ($4.60) | ($2.68) | ($7.45) | ($21.75) | ($49.99) | ($17.99) |
| Shares outstanding (diluted) | 30.6 | 19.2 | 12.0 | 11.2 | 3.4 | 0.8 | 0.3 | 0.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|